check_circleStudy Completed
Treatment of venous thromboembolism in cancer patients,
Bayer Identifier:
22020
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
A study to gather information about rivaroxaban in patients in the United Kingdom who have cancer and thrombosis (OSCAR—UK)
Trial purpose
Patients with cancer are more likely than those without cancer to develop blood clots (deep vein thrombosis and pulmonary embolism), which are treated using blood thinners (anticoagulants). When clots occur, cancer patients carry a higher risk of recurring clots and more likely to bleed on blood thinning treatments. Therefore, it is critical to use blood thinners that optimize the safety and benefits.
There are two main types of blood thinners that are recommended. The tablets which are direct-acting oral anticoagulants and the injections (low molecular-weight heparin). Clinical trials show the tablets may reduce clot risk but may potentially lead to more frequent bleeding, particularly in those with certain risk factors such as stomach ulcers, previous bleeding problems, certain cancer type.
We aim to examine the effectiveness and safety of the tablets versus the injections for treatment of clots in cancer patients, to better understand these treatments' benefits and risks.
There are two main types of blood thinners that are recommended. The tablets which are direct-acting oral anticoagulants and the injections (low molecular-weight heparin). Clinical trials show the tablets may reduce clot risk but may potentially lead to more frequent bleeding, particularly in those with certain risk factors such as stomach ulcers, previous bleeding problems, certain cancer type.
We aim to examine the effectiveness and safety of the tablets versus the injections for treatment of clots in cancer patients, to better understand these treatments' benefits and risks.
Key Participants Requirements
Sex
AllAge
18 - N/ATrial summary
Enrollment Goal
2601Trial Dates
December 2021 - August 2022Phase
Phase 4Could I Receive a placebo
NoProducts
UnspecifiedAccepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many locations | Many locations, United Kingdom |
Primary Outcome
- The risk of recurrent VTE at 3-monthsdate_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- Composite of any major bleeding or clinically-relevant non-major bleeding-related hospitalization at 3-monthsPer the International Society on Thrombosis and Haemostasis (ISTH) criteria [9, 10] for identification of bleeding-associated hospitalizations.date_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- All-cause mortality at 3-monthsdate_rangeTime Frame:Retrospective data analysis from 2013 to 2020
Secondary Outcome
- Recurrent VTE at 6- and 12-months post-index VTEdate_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- Composite of any major or clinically-relevant non-major bleeding-related hospitalization at 6- and 12-months post-index VTEIncluding: - Intracranial hemorrhage (ICH) - Critical organ bleeding (e.g., intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial bleeding or intramuscular with compartment syndrome) - Extracranial bleeding-related hospitalizations (including trauma-related)date_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- Composite of any major bleeding or clinically-relevant non-major bleeding-related hospitalization at 6 and 12-monthsPer the ISTH criteria [9, 10] for identification of bleeding-associated hospitalizations.date_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- Intracranial hemorrhage (ICH), critical organ bleeding and extracranial bleeding-related hospitalizations as separate outcomesdate_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- All-cause mortality at 6- and 12-monthsdate_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- Incidence rates of recurrent VTE in rivaroxaban, DOAC and LMWH patients experiencing cancer-associated thrombosis (CAT) regardless of the bleeding risk associated with cancer typedate_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- Any clinically-relevant bleeding-related hospitalization in rivaroxaban, DOAC and LMWH patients experiencing cancer-associated thrombosis (CAT) regardless of the bleeding risk associated with cancer typedate_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- All cause-mortality in rivaroxaban, DOAC and LMWH patients experiencing cancer-associated thrombosis (CAT) regardless of the bleeding risk associated with cancer typedate_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- Duration of anticoagulation treatmentdate_rangeTime Frame:Retrospective data analysis from 2013 to 2020
- Discontinuation rates of rivaroxaban, DOAC and LMWH at 3-, 6-, 12-months and all available follow-update_rangeTime Frame:Retrospective data analysis from 2013 to 2020
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
OtherAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A